Home›Screener›ARVN›Profile
F
35/100

Arvinas Inc

ARVNProtein Degradation
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Arvinas Inc (ARVN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 2 Phase 1[2].

ARVN has 2 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001655759 (2026-04-11) ↗
🔬
Clinical Trials
2
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07023731KRAS G12D Mutation, Advanced Solid Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
2 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Protein Degradation)
GLUEMonte Rosa Therapeutics
D
NRIXNurix Therapeutics
D
KYMRKymera Therapeutics
D
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR